medigraphic.com

2008, Number S2

<< Back Next >>

Arch Cardiol Mex 2008; 78 (S2)

Extreme elevation of the blood pressure (hypertensive crisis): recommendations for its clinical-therapeutic boarding

Mendoza-González C, Rosas M, Lomelí EC, Lorenzo JA, Méndez A, Martínez-Reding J, Martínez-Sánchez C, Pastelín G, Férez-Santander SM, Attie F

Language: Spanish
References: 61
Page: 74-81
PDF size: 127.33 Kb.


ABSTRACT

From beginnings of last century the hypertensive emergency was defined as the association of acutely elevation from the arterial pressure and the appearance of damage to end organ. At present is recognized the effects of the hypertensive emergency, the aspects of its patophysiology in which are included phenomenon of vasomotricity and the participation of different substances with vasoactives properties. The clinical presentation includes not only the manifestations of the increase of the arterial pressure, the end organ damage too; for this reason the hypertensive emergency needs the immediate reduction of the arterial tension to prevent the damage to specific organs. The treatment in every case will have to be individualized, with a wide knowledge of the characteristics of every medicament to obtain the best results. The diagnosis and treatment of the hypertensive emergencies needs often of the attention of its complications if they have appeared and later, of a treatment of support for the arterial hypertension.


REFERENCES

  1. Marik PE, Varon J: Hypertensive crises. Challenges and Management. Chest 2007; 131: 1949-1962.

  2. Volhard F, Fahr T: Die brightsche Nierenkranbeit: Klinik, Pathologie und Atlas. Berlin, Germany: Springer, 1914.

  3. Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332-343.

  4. Laragh J: Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14: 837-854.

  5. McRae RPJ, Liebson PR: Hypertensive crisis. Med Clin North Am 1986; 70: 749-767.

  6. Vidt DG: Current concepts in treatment of hypertensive emergencies. Am Heart J 1986; 111: 220-225.

  7. Hyattsville MD: Vital and health statistics: detailed diagnoses and procedures for patients discharged from short-stay hospitals: United States, 1983-1990. National Center for Health Statistics, 1997.

  8. Tisdale JE, Huang MB, Borzak S, et al: Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Fam Pract 2004; 21: 420-424.

  9. Shea S, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992; 327: 776-781.

  10. Tumlin JA, Dunbar LM, Oparil S, et al: Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial: fenoldopam Study Group. Acad Emerg Med 2000; 7: 653-662.

  11. Ault MJ, Ellrodt AG: Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med 1985; 3: 10-15.

  12. Wallach R, Karp RB, Reves JG, et al: Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 1980; 46: 559-565.

  13. Funakoshi Y, Ichiki T, Ito K, et al: Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 1999; 34: 118-125.

  14. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor- B transcription factors. Circ Res 1999; 84: 695-703.

  15. Zampaglione B, Pascale C, Marchisio M, et al: Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996; 27: 144-147.

  16. Varon J, Marik PE: The diagnosis and management of hypertensive crises. Chest 2000; 118: 214-227.

  17. Rey E, LeLorier J, Burgess E, et al: Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. Can Med Assoc J 1997; 157: 1245-1254.

  18. Hickler RB: Hypertensive emergency: a useful diagnostic category. Am J Public Health 1988; 78: 623-624.

  19. Garcia JYJ, Vidt DG: Current management of hypertensive emergencies. Drugs 1987; 34: 263-278.

  20. Fromm RE, Varon J, Gibbs L: Congestive heart failure and pulmonary edema for the emergency physician. J Emerg Med 1995; 13: 71-87.

  21. Gandhi SK, Powers JC, Nomeir AM, et al: The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-22.

  22. Strandgaard S, Olesen J, Skinhoj E, et al: Autoregulation of brain circulation in severe arterial hypertension. BMJ 1973; 1: 507-510.

  23. Khan IA, Nair CK: Clinical, diagnostic, and management perspectives of aortic dissection. Chest 2002; 122: 311-328.

  24. Estrera AL, Miller CC III, Safi HJ, et al: Outcomes of medical management of acute type B aortic dissection. Circulation 2006; 114: I384-I389.

  25. Khot UN, Novaro GM, Popovic ZB, et al: Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756-1763.

  26. DiPette DJ, Ferraro JC, Evans RR, et al: Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther 1985; 38: 199-204.

  27. Hirschl MM, Binder M, Bur A, et al: Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises. J Hum Hypertens 1997; 11: 177-183.

  28. Kanot J, Allonen H, Kleimola T, et al: Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1981; 19: 41-44.

  29. Goldberg ME, Clark S, Joseph J, et al: Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J 1990; 119: 446-450.

  30. Pearce CJ, Wallin JD: Labetalol and other agents that block both - and -adrenergic receptors. Cleve Clin J Med 1994; 61: 5-69.

  31. Wallin JD: Adrenoreceptors and renal function. J Clin Hyperten 1985; 1: 171-178.

  32. Marx PG, Reid DS: Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 1979; 8: 233S-238S.

  33. Olsen KS, Svendsen LB, Larsen FS, et al: Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 1995; 75: 51-54.

  34. Schillinger D: Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med 1987; 5: 463-473.

  35. Lambert CR, Hill JA, Feldman RL, et al: Effects of nicardipine on left ventricular function and energetics in man. Int J Cardiol 1986; 10: 237-250.

  36. Mann T, Cohn PF, Holman LB, et al:. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease: results in 25 patients and comparison with nitroglycerin. Circulation 1978; 57: 732-738.

  37. Cohn JN, Franciosa JA, Francis GS, et al: Effect of shortterm infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306: 1129-1135.

  38. van Harten J, Burggraaf K, Danhof M, et al: Negligible sublingual absorption of nifedipine. Lancet 1987; 2: 1363-1365.

  39. Huysmans FT, Sluiter HE, Thien TA, et al: Acute treatment of hypertensive crisis with nifedipine. Br J Clin Pharmacol 1983; 16: 725-727.

  40. Grossman E, Messerli FH, Grodzicki T, et al: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328-1331.

  41. Bussmann WD, Kenedi P, von Mengden HJ, et al: Comparison of nitroglycerin with nifedipine in patients with hypertensive crisis or severe hypertension. Clin Investig 1992; 70: 1085-1088.

  42. Schroeder HA: Effects on hypertension of sulfhydryl and hydrazine compounds. J Clin Invest 1951; 30: 672-673.

  43. Shepherd AM, Ludden TM, McNay JL, et al: Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 1980; 28: 804-811.

  44. Ludden TM, Shepherd AM, McNay JL, et al: Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther 1980; 28: 736-742.

  45. Kouchoukos NT, Dougenis D: Surgery of the thoracic aorta. N Engl J Med 1997; 336: 1876-1888.

  46. Chen K, Varon J, Wenker OC, et al: Acute thoracic aortic dissection: the basics. J Emerg Med 1997; 15: 859-867.

  47. O’Connor B, Luntley JB: Acute dissection of the thoracic aorta: esmolol is safer than and as effective as labetalol. BMJ 1995; 310: 875.

  48. Hoshino T, Ohmae M, Sakai A: Spontaneous resolution of a dissection of the descending aorta after medical treatment with a blocker and a calcium antagonist. Br Heart J 1987; 58: 82-84.

  49. Iguchi A, Tabayashi K: Outcome of medically treated Stanford type B aortic dissection. Jpn Circ J 1998; 62: 102-105.

  50. Britton M, Carlsson A, de Faire U: Blood pressure course in patients with acute stroke and matched controls. Stroke 1986; 17: 861-864.

  51. Wahlgren NG, MacMohon DG, De Keyser J, et al: The Intravenous Nimodipine West Europen Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994; 4: 204-210.

  52. Ahmed N, Nasman P, Wahlgren NG:. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000; 31: 1250-1255.

  53. Adams HP Jr, Adams RJ, Brott T, et al: Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-1083.

  54. The European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 2003; 16: 311-337.

  55. Semplicini A, Maresca A, Boscolo G, et al: Hypertension in acute ischemic stroke: a compensatory mechanism or an additional damaging factor? Arch Intern Med 2003; 163: 211-216.

  56. Adams H, Adams R, Del ZG, et al: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update; a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.

  57. Schrader J, Luders S, Kulschewski A, et al: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703.

  58. Qureshi AI, Harris-Lane P, Kirmani JF, et al: Treatment of acute hypertension in patients with intracerebral hemorrhage using American Heart Association guidelines. Crit Care Med 2006; 34: 1975-1980.

  59. Hollander JE: The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333: 1267-1272.

  60. Boehrer JD, Moliterno DJ, Willard JE, et al: Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993; 94: 608-610.

  61. Moore NA, Rees G, Sanger G, et al: Effect of L-type calcium channel modulators on stimulant-induced hyperactivity. Neuropharmacology 1993; 32: 719-720.




2020     |     www.medigraphic.com